Get the Daily Brief
Latest Biotech News
VT3989 demonstrates early activity in refractory mesothelioma
The University of Texas MD Anderson Cancer Center reported promising early outcomes from trials of VT3989, a first‑in‑class YAP‑TEAD inhibitor, in refractory mesothelioma and other solid tumors....
Syngene builds automated peptide lab to speed discovery
India‑based Syngene International completed site upgrades, opening a dedicated peptide laboratory in Bengaluru and deploying advanced automation across DMPK and Direct‑to‑Biology (D2B) workflows....
FDA exodus and voucher program scrutiny reshape regulatory backdrop
BioCentury analysis quantified a recent staffing drain at the FDA—reporting that one in seven CBER and one in eight CDER employees exited in fiscal Q4—raising concerns about the agency’s capacity...
Grail’s Galleri improves accuracy: FDA filing nears
New large-study data show improvements in Grail’s Galleri multi-cancer screening test as the company moves toward broader regulatory review. Results from the PATHFINDER 2 U.S. study—presented at...
FDA unveils nine 'national priority' picks — review clock shortens
The FDA has selected the first nine products for its Commissioner’s National Priority Review Voucher pilot, a program designed to compress review timelines for candidates that address national...
Sophia Genetics launches Digital Twins: AI models simulate cancer patients
Sophia Genetics unveiled Sophia DDM Digital Twins at the ESMO conference, an AI-driven module that builds computational replicas of individual cancer patients using multimodal clinical, genomic...
New mesothelioma agents show activity: YAP‑TEAD inhibitor and Vivace readouts
Two separate midstage programs reported activity in treatment-resistant mesothelioma. Researchers at MD Anderson disclosed early results for VT3989, a first-in-class YAP‑TEAD inhibitor that...
ADCs encroach on first‑line TNBC: head‑to‑head presentations shift treatment choices
At ESMO, competing antibody‑drug conjugates (ADCs) from AstraZeneca/Daiichi Sankyo and Gilead were presented back-to-back with positive Phase 3 data in metastatic triple‑negative breast cancer...
Tubulis clinical win follows big funding: investor thesis validated
Tubulis reported first‑in‑human data for its next‑generation ADC TUB‑040 with an overall response rate of 59% across dose cohorts in heavily pretreated patients, data the company released shortly...
mRNA COVID shots linked to better checkpoint immunotherapy outcomes
Clinical teams reported independent observations that receipt of mRNA COVID‑19 vaccines near the time of checkpoint inhibitor therapy coincided with improved outcomes in advanced cancer patients....
Tumor‑infiltrating Fusobacterium induces quiescence and blunts chemotherapy
MD Anderson researchers described a mechanism by which tumor‑infiltrating bacteria—chiefly Fusobacterium nucleatum—physically surround epithelial tumor cells, disrupt cell‑cell communication and...
SDR‑seq decodes noncoding DNA and RNA from the same cell
EMBL researchers unveiled SDR‑seq, a single‑cell sequencing method that captures both DNA and RNA from the same cell to expose functional non‑coding variants that influence gene regulation....
Rutgers maps molecular route to AML therapy resistance
Researchers from Rutgers and international collaborators identified a molecular mechanism that underlies therapy resistance in acute myeloid leukemia (AML), offering new targets to overcome...
AstraZeneca ADC push: Enhertu moves earlier; AZD5335 posts activity
AstraZeneca presented clinical data showing its antibody-drug conjugate (ADC) franchise is advancing beyond late-stage disease. At ESMO, investigators reported Enhertu produced meaningful benefit...
Tubulis’ platform vindicated — 59% response riles investors
Tubulis reported first‑in‑human data for its NaPi2b‑targeting ADC, TUB‑040, showing a confirmed overall response rate of 59% across multiple dose cohorts in heavily pretreated patients. The...
TNBC ADC showdown: Datroway versus Trodelvy — clinicians to choose
Two late‑stage ADCs targeting metastatic triple‑negative breast cancer (TNBC) produced compelling Phase 3 data presented back‑to‑back at ESMO. AstraZeneca/Daiichi Sankyo’s Datroway and Gilead’s...
Grail’s Galleri: improved specificity as FDA filing approaches
Grail released new PATHFINDER study results showing improved positive predictive value for its multi‑cancer Galleri blood test, findings that company executives argue strengthen its case for...
FDA pilot: first nine CNPV picks aim to speed review — winners named
The U.S. Food and Drug Administration revealed the first nine recipients of its Commissioner’s National Priority Voucher (CNPV) pilot program, a fast‑track mechanism intended to deliver regulatory...
mRNA COVID vaccines boost checkpoint immunotherapy — ESMO findings
Data presented at ESMO and at MD Anderson indicate that patients who received an mRNA COVID‑19 vaccine within 100 days prior to starting immune checkpoint inhibitors had longer survival than those...
Microbes and mechanics: bacteria and cell 'craters' reshape tumor resistance story
MD Anderson researchers reported that tumor‑infiltrating bacteria, notably Fusobacterium nucleatum, can induce quiescence in cancer epithelial cells, enabling immune evasion and chemotherapy...